Pharma Deals Review, Vol 2005, No 64 (2005)

Font Size:  Small  Medium  Large

NexMed Signs Global Licensing Deal with Novartis

Business Review Editor

Abstract


NexMed has licensed a nail fungal infection treatment that utilizes its proprietary drug delivery technology NexACT® to Novartis. The deal could worth up to US$51 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.